| 10.54++# | | | Manufacturing Services and Line Retention Agreement between Insulet Corporation and Flex Medical Sales and Marketing, Ltd., dated July 29, 2022 | | |
| 10.55++# | | | Amendment Number 15 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated July 12, 2017 | | |
| 10.56++# | | | Amendment Number 17 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated April 1, 2019 | | |
| 10.57++# | | | Amendment Number 18 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated August 1, 2019 | | |
| 10.58++# | | | Amendment Number 19 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated July 13, 2020 | | |
| 10.59++# | | | Amendment Number 20 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated June 25, 2021 | | |
| | | | | |
| 10.60++ | | | Patent Assignment and License Agreement, dated February 9, 2023, between Insulet Corporation, Bigfoot Biomedical, Inc. and Patients Pending, Ltd. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed February 14, 2023) | | |
| | | | | |
| 10.61* | | | Form of Insulet Corporation 2017 Stock Option and Incentive Plan Non-Qualified Stock Option Agreement (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed February 22, 2023) | | |
| | | | | |
| 10.62* | | | Form of Insulet Corporation 2017 Stock Option and Incentive Plan Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K, filed February 22, 2023) | | |
| | | | | |
| 10.63* | | | Form of Insulet Corporation 2017 Stock Option and Incentive Plan Performance Stock Unit Agreement (Incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K, filed February 22, 2023) | | |
| | | | | |
| 10.64* | | | Annual Incentive Compensation Plan (Incorporated by reference to Exhibit 10.5 to our Current Report on Form 8-K, filed February 22, 2023) | | |
| | | | | |
| 10.65* | | | Consulting Services Agreement by and between the Company and Charles J. Alpuche (Incorporated by reference to Exhibit 10.6 to our Current Report on Form 8-K, filed February 22, 2023) | | |
| | | | | |
| 10.66*# | | | Form of Confidentiality, Non-Solicit, Non-Compete, and IP Assignment Agreement, by and between the Company and Employee (Jim Hollingshead and Dan Manea) | | |
| | | | | |
| 21.1# | | | Subsidiaries of the Registrant | | |
| | | | | |
| 23.1# | | | Consent of Independent Registered Public Accounting Firm (Grant Thornton LLP) | | |
| | | | | |
| 24.1# | | | Power of Attorney (included on signature page) | | |
| | | | | |
| 31.1# | | | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer | | |
| | | | | |
| 31.2# | | | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer | | |
| | | | | |
| 32.1** | | | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Chief Executive Officer and Chief Financial Officer | | |
| | | | | |
| 101 | | | The following materials from Insulet Corporation’s Annual Report on Form 10-K for the year ended December 31, 2022 formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Operations; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Stockholders’ Equity; (v) the Consolidated Statements of Cash Flows | | |